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This study reveals that the activation of either PPARa (WY 14 643) or PPARb (GW0742) each induce
the translocation of FAT/CD36 from an intracellular pool(s) to the plasma membrane, while PPARb
also induces the subcellular redistribution of FABPpm(Got2) to the plasma membrane. In contrast,
activation of PPARc failed to induce the subcellular redistribution of FAT/CD36 and FABPpm. These
PPARa-, and PPARb-induced changes in the plasmalemmal content of these fatty acid transporters
were associated with the concurrent upregulation of fatty acid triacylglycerol esteriﬁcation (PPARb)
and oxidation (PPARa and PPARb). Observed effects of chronic PPAR stimulation were not related to
either AMPK or ERK1/2 activation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Long chain fatty acids (LCFAs) are predominant energy sub-
strates for the heart [1,2] and thus, the uptake of LCFAs into cardio-
myocytes is an essential step in cardiac energy homeostasis. Based
on LCFAs hydrophobic properties, it has been proposed that, they
cross the plasma membrane by simple diffusion [3,4]. However, re-
cent studies have shown that the majority of LCFAs are taken up by
cardiac myocytes via a protein-mediated mechanism [5–7]. So far
three groups of proteins have been identiﬁed that contribute to
this process: fatty acid translocase (FAT/CD36), plasma membrane
associated fatty acid binding protein (FABPpm; Got2) and fatty acid
transport proteins 1–6 (FATP1–6) [8–10]. Among them FAT/CD36
and FABPpm were found to be the key fatty acid transporters in
the heart as the expression of these proteins in cardiomyocytes is
highly abundant [7,9].
Myocardial expression of LCFA transporters is modulated
through both transcriptional and post-transcriptional mecha-
nisms [11]. However, recent studies strongly suggest that only
plasmalemmal abundance of LCFA transporters determines the
cardiac myocyte capacity for fatty acid uptake [12–16]. Accord-
ingly it was shown that the rates of LCFA transport are upregu-
lated, due to the translocation of LCFA transporters from itschemical Societies. Published by E
ki).intracellular depot to the plasma membrane. Therefore, by regu-
lating the rate of entry of LCFAs into the cells, these LCFA
transport proteins may serve as a key factor contributing to the
regulation of lipid metabolism in healthy hearts, whereas in obes-
ity and diabetes they may contribute to the development of lipo-
toxicity characterized by the excess of lipid accumulation in the
heart [2,5,17–19].
Recent studies have demonstrated an important role for the
peroxisome proliferator-activated receptors (PPARs) in the tran-
scriptional control of genes involved in cardiac fatty acid uptake
and oxidation [20–23]. PPARs are ligand-activated transcription
factors of the nuclear hormone receptor superfamily. Three distinct
PPAR isoforms termed a, b/d and c have been described in the
heart, but PPARa and d are relatively abundantly expressed [24–
26]. PPARa activation has been shown to stimulate fatty acids uti-
lization in the heart through the transcriptional control of genes
responsible for cardiac fatty acid (FA) uptake, esteriﬁcation and
b-oxidation [21,22,27]. Similarly, PPARb/d stimulation leads to
augmentation of FA transport and oxidation in cardiac myocytes.
Importantly these effects were independent of PPARa activation
[22,28,29]. The content of PPARc isoform in cardiac muscle cells
is relatively low and its role in cardiac metabolism is still unclear.
However, there are indications that PPARc stimulation, in contrast
to a and d activation, attenuates fatty acid transmembrane inﬂow
and metabolism while stimulating glucose utilization [22,30].
Taken altogether, there is considerable evidence that PPARlsevier B.V. All rights reserved.
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olism [23,29–31].
Despite recent studies, little is known regarding the inﬂuence of
in vivo PPAR activation on lipid metabolism in the heart muscle,
especially their independent effects on LCFAs transport mediated
by fatty acid transport proteins. Therefore, we investigated the ef-
fects of chronic, in vivo, PPARs stimulation on the expression (pro-
tein and mRNA) and subcellular distribution of the key fatty acid
transporters FAT/CD36 and FABPpm in cardiac myocytes, and on
the rates of fatty acid transport and FA metabolism in the heart.2. Materials and methods
2.1. Materials
FAT/CD36 and FABPpm were detected as reported previously
[32,33] using the (ab 36977, Abcam, UK) and FABPpm antisera (a
gift from Dr. Calles-Escandon), respectively. The total and phos-
phorylated quantities of selected cytosolic proteins were deter-
mined with commercially available antibodies total and
phospho-ERK1/2 (Thr202/Thr204) and total and phospho-AMPK
(Thr172), (Cell Signaling Technology, Beverly, MA). [3H]-palmitate
was purchased from Amersham Life Science (Little Chalfont, UK).
Appropriate secondary antibodies were purchased from Abcam
UK or Cell Signaling Technology (Beverly, MA). All other chemicals
were obtained from Sigma–Aldrich (St. Louis, MO).
2.2. Methods
Male Wistar rats (250–300 g) were bred on site and maintained
at 20 oC on a reverse light-dark cycle in approved animal holding
facilities. They had unrestricted access to food (standard chow)
and water. The animals were divided into four groups: (i) control
(receiving only 0.5% methylcellulose by an oral gavage), or treated
daily for 2 weeks by oral gavage with a selective (ii) PPARa agonist
(WY 14 643, 3 mg/kg body weight), (iii) PPARc agonist (pioglitaz-
one, 3 mg/kg body weight, Actos, Lilly) or (iv) PPAR b/d agonist
(GW0742, 3 mg/kg body weight, Cayman Chemicals). In each group
the palmitate oxidation and palmitate incorporation into different
lipid pools in the heart was measured. Total (protein and mRNA)
FAT/CD36 and FABPpm expressions as well as their plasma mem-
branes (PM) and low density microsomes (LDM) content were
determined. This study was approved by the Ethical Committee
for Animal Experiments at the Medical University of Bialystok.
2.2.1. Palmitate oxidation and incorporation into different lipid pools
To examine the effects of PPAR’s stimulation on palmitate
metabolism, we used intact hearts that were perfused in the
Langendorff perfusion mode. Brieﬂy, after removing hearts from
anaesthetized rats (Vetbutol (50–60 mg/100 g, i.p.), combined with
heparin (300 i.u./100 g, i.p.)), the hearts were perfused for a 5 min
equilibration period with Krebs Henseleit buffer (KHB). Subse-
quently, the hearts were switched to KHB containing 3H-palmitate
(100 lmol/l with a corresponding palmitate-to-BSA ratio of 0.3 and
continuously gassed for 15 min under normoxic (37 oC, 95% O2 and
5% CO2) conditions). Thereafter, hearts were removed and immedi-
ately freeze-clamped in liquid nitrogen and stored at 80 oC until
analyzed. Heart lipids were extracted according to van der Vusse
et al. [34], with modiﬁcation as we previously described [35]. Fro-
zen heart samples were pulverized in an aluminium mortar with a
stainless steel pestle, both pre-cooled in liquid nitrogen. The pow-
der was transferred into glass tubes containing 2 ml of methanol at
20 C. Subsequently, 4 ml of chloroform was added. Lipids from
chloroform layer were separated into different fractions by means
of thin-layer chromatography (silica plate 60, 0.25 mm, Merck)using heptane: isopropyl ether:acetic acid (60:40:3, v/v/v) as a sol-
vent. After drying, the plates were sprayed with a 0.2% solution of
20,70-dichloroﬂuorescein in methanol and exposed shortly to
ammonia vapours. The lipid bands, localized under UV light and
identiﬁed according to the standards (Sigma, St. Louis, MO), were
scraped off the plates. Finally, samples were dissolved in hexane
and the 3H-palmitate incorporation into different lipid pools was
determined. Water-soluble phase of the samples was transferred
immediately into scintillation vials and counted for radioactivity
(palmitate oxidation). Oxidation rates of 3H-palmitate were also
determined by measuring the release of 3H2O and other water sol-
uble intermediates into the buffer at the end of the Langendorff
perfusion. The validity of using rates of 3H2O production from
3H-palmitate as a measure of palmitate oxidation has been previ-
ously described [36]. In brief, 3H2O was separated from 3H-palmi-
tate by treating 0.5 ml perfusion buffer with a mixture of
chloroform and 2 M KCL:HCL solution. The aqueous phase was
then collected and subsequently treated with a mixture of
chloroform, methanol and KCL:HCL (1:1:0.9 vol/vol/vol). Subse-
quently, the aqueous phase was removed and counted for radioac-
tivity. This technique results in an extraction and separation of
3H2O from 3H-palmitate, as has been reported previously [36].
The palmitate oxidation was counted as a sum of the 3H2O and
water soluble intermediates present in the heart muscle tissue
and in the perfusion buffer at the end of the Langendorf perfusion.
Simpliﬁcated palmitate uptake was estimated as a sum of the oxi-
dation and the esteriﬁcation.
2.2.2. Subcellular fractionation of intact perfused hearts
To relate changes in the palmitate metabolism with fatty acid
transporters we examined the protein expression and the subcellu-
lar distribution of fatty acid transporters. For these purposes con-
trol and PPAR’s stimulated hearts were prepared as described
above, frozen in liquid nitrogen and stored at 80 oC until ana-
lyzed. Subcellular fractionation was performed using procedures
previously described [14–16,37]. Upon thawing, hearts were diced
and incubated for 30 min in a high-salt solution (2 mol/l NaCl,
20 mmol/l HEPES pH 7.4, and 5 mmol/l NaN3) at 4 C as recom-
mended by Fuller et al. [38]. Thereafter, the suspension was centri-
fuged for 5 min at 1000g and the pellet homogenized in 6.0 ml
TES-buffer using a tightly ﬁtting 10-ml Potter-Elvejhem glass
homogenizer with 10 strokes. The resulting homogenate was cen-
trifuged for 5 min at 1000g, after which the pellet was rehomog-
enized in 4.0 ml TES-buffer with 10 strokes and then recombined
with the 1000g supernatant. The homogenate was centrifuged
for 10 min at 100g. The pellet (P1) was resuspended in 300 ll
TES-buffer and saved. The supernatant was centrifuged for
10 min at 5000g. The pellet (P2) was resuspended in 300 ll
TES-buffer and saved. The supernatant was centrifuged for
20 min at 20 000g. The pellet (P3) was resuspended in 300 ll
TES-buffer and saved. The supernatant was centrifuged for
30 min at 48 000g. The pellet (P4) was resuspended in 150 ll
TES-buffer and saved. The supernatant was centrifuged for
65 min at 250 000g. The pellet (P5) was resuspended in 150 ll
TES-buffer and saved. Upon analysis of P1–P5 with ouabain-sensi-
tive p-nitrophenyl-phosphatase and with EGTA-sensitive Ca2+-
ATPase, it has been established that fractions P2 refers as PM-frac-
tion and P5 as LDM fraction [14–16,37,39].
2.2.3. Western blotting
The total expression of FAT/CD36 and FABPpm protein was
determined in hearts homogenates yielding crude membranes, as
described previously [37,39]. The content of FAT/CD36 and FAB-
Ppm was also determined in PM and LDM fractions obtained from
subfractionated hearts, as described in previous section. The
cytosolic proteins were detected in heart homogenates as de-
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bicinchoninic acid method with BSA serving as a protein standard
Signals obtained byWestern blotting were quantiﬁed by densitom-
etry (BioRad, Poland). Routine Pancou S staining was used to en-
sure equal protein loading [14,15,37].
All data are expressed as mean ± S.E.M. Statistical difference be-
tween groups was tested with analyses of variance and appropriate
post hoc tests, or with a t-test. Statistical signiﬁcance was set at
P 6 0.05.
2.2.4. FAT/CD36 and FABPpm mRNA
Total RNA was isolated from the heart tissue using a commer-
cially available Total RNA Isolation Kit (A&A Biotechnology, Poland)
as outlined by the manufacturer. Following RNA puriﬁcation,
DNAse treatment (Ambion, UK) was performed to ensure there
was no genomic DNA contamination. Real time qPCR was per-
formed using a Chromo 4 System (Bio-Rad, Poland) by SYBR Green
JumpStart Taq ReadyMix (Sigma, USA). Relative FATCD36 and FAB-
Ppm (gene name Got2) RNA levels were calculated using the DDCT
method and b-actin served as internal control. The following pri-
mer sets were used: (1) FAT/CD36: forward: 50-GCAACAACAAGGC-
CAGGTAT-30 and reverse: 50-AAGAGCTAGGCAGCATGGAA-30, (2)
FABPpm: forward: 50-TCATCCTTTTGTCTCCAGCTTTT-30 and re-
verse: 50-CCTATGCCATGCTGACAGGT-30, (3) b-actin: forward: 50-
CACACCCGCCACCAGTTC-30 and reverse: 50-GTAGGAGTCCTTCTG
ACCCATAC-30.
3. Results
3.1. Effects of PPARs on fatty acid transporters
3.1.1. Effects of PPARa stimulation on the total expression and
subcellular redistribution of FAT/CD36 and FABPpm in heart
Chronic in vivo PPARa activation did not change the total myo-
cardial protein expression of either FAT/CD36 or FABPpm, althoughFig. 1. Effects of PPARa stimulation on: (1) total protein expression, (2) mRNA and (3) th
are shown. Data are based on 10 independent determinations. PM: plasma membranes,the transcript mRNA was signiﬁcantly elevated for FAT/CD36 (1.7-
fold, P < 0.05). PPARa stimulation induced also the redistribution of
FAT/CD36 from an intracellular pool (LDM: 25%, P < 0.05) to the
plasma membranes (PM: +33%, P < 0.05). In contrast, FABPpm sub-
cellular distribution remained constant (LDM: 5% and PM: +6%,
P > 0.05) (Fig. 1).
3.1.2. Effects of PPARb/d stimulation on the total expression and
subcellular redistribution of FAT/CD36 and FABPpm in heart
Treatment with PPARb/d agonist increased the myocardial
expression of FAT/CD36 at the (1) protein level (+20%, P < 0.05)
and (2) mRNA (+2.1-fold, P < 0.05), but had no signiﬁcant effect
on FABPpm expression (protein: +5%, P > 0.05 and mRNA: +1.3-
fold, P > 0.05). Surprisingly, PPARb/d stimulation induced the trans-
location of both FAT/CD36 and FABPpm to the plasma membranes
(PM: +55% and +15%, P < 0.05, respectively) while concomitantly
reducing the content of FAT/CD36 and FABPpm in the intracellular
fraction (LDM: 45% and 10%, P < 0.05, respectively) (Fig. 2).
3.1.3. Effects of PPARc stimulation on the total expression and
subcellular redistribution of FAT/CD36 and FABPpm in heart
In contrast to PPARa and PPARd stimulation, chronic PPARc
activation did not alter the myocardial total expressions (protein
and mRNA) of either FAT/CD36 and FABPpm, and had no signiﬁcant
inﬂuence on their redistribution from an intracellular pool (LDM:
P > 0.05, respectively) to the plasma membranes (PM: P > 0.05,
respectively) (Fig. 3).
3.2. Effects of PPARs on fatty acid metabolism
3.2.1. Effects of PPARa stimulation on the esteriﬁcation and oxidation
of palmitate in intact, perfused heart
In Langendorff perfused hearts, chronic PPARa stimulation, in-
duced signiﬁcant increase in the incorporation of radiolabelled pal-
mitate into only myocardial diacylglycerols (+28%, P < 0.05). Theree subcellular redistribution of FAT/CD36 and FABPpm. Representative Western blots
LDM: low density microsomes. *P < 0.05, PPARa stimulation vs. control.
Fig. 2. Effects of PPARb/d stimulation on: (1) total protein expression, (2) mRNA and (3) the subcellular redistribution of FAT/CD36 and FABPpm. Representative Western blots
are also shown. Data are based on 10 independent determinations. PM: plasma membranes, LDM: low density microsomes. *P < 0.05, PPARb/d stimulation vs. control.
Fig. 3. Effects of PPARc stimulation on: (1) total protein expression, (2) mRNA and (3) the subcellular redistribution of FAT/CD36 and FABPpm. Representative Western blots
are also shown. Data are based on 10 independent determinations. PM: plasma membranes, LDM: low density microsomes. *P < 0.05, PPARc stimulation vs. control.
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lipid or triacylglycerol lipid fractions (Fig. 4A). A consistent in-
crease in palmitate oxidation after PPARa activation also
occurred (+40%, P < 0.05) (Fig. 4B).3.2.2. Effects of PPARb/d stimulation on the esteriﬁcation and oxidation
of palmitate in intact, perfused hearts
Stimulation of PPARb/d did not induce signiﬁcant changes in the
incorporation of radiolabelled palmitate into phospholipids nor
Fig. 4. Effects of PPAR‘s stimulation on: (A) the esteriﬁcation and (B) oxidation of
palmitate in intact, Langendorff perfused hearts. Data are based on 10 independent
determinations for each treatment (mean sem). PL: phospholipids, DG: diacylgly-
cerols, TG: triacylglycerols. *P < 0.05, PPAR’s stimulation vs. control.
ig. 5. Correlation between the effects of PPAR’s stimulation on the palmitate
ptake and plasmalemmal fatty acid transporters expression (as expressed relative
control = 100).
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radioactivity in triacylglycerol myocardial lipid fraction (+34%,
P < 0.05) (Fig. 4A). We also found that palmitate oxidation was sig-
niﬁcantly greater after PPARb/d activation (+56%, P < 0.05) (Fig. 4B).
3.2.3. Effects of PPARc stimulation on the esteriﬁcation and oxidation
of palmitate in intact, perfused hearts
In contrast to the PPARa and PPARb/d activation, palmitate
myocardial oxidation after PPARc stimulation decreased signiﬁ-
cantly (42%, P < 0.05) (Fig. 4B). Simultaneously, there were no sig-
niﬁcant changes in palmitate incorporation into different lipid
pools in the intact perfused hearts (Fig. 4A).
3.2.4. Effects of PPAR’s stimulation on the palmitate uptake in intact,
perfused hearts
In Langendorff perfused hearts, palmitate uptake was signiﬁ-
cantly increased after PPARa and PPARb/d chronic stimulation,
whereas there was no change followed PPARc activation. We ob-
served that the changes in the palmitate uptake after PPAR’s stim-
ulation distinctly correlated with the changes in plasmalemmal
content of FAT/CD36 (Fig. 5).
3.2.5. Effects of PPAR’s stimulation on cytosolic expression of AMPK
and ERK1/2
In vivo, activation of different PPAR‘s had no effect on either the
total or phoshorylated protein expression of AMPK and ERK1/2
(Fig. 6).4. Discussion
Our present study reveals, that the activation of either PPARa
(WY 14 643) or PPARb/d (GW0742) each induce the translocation
of FAT/CD36 from an intracellular pool(s) to the plasmamembrane,
while PPARb/d also induces the subcellular redistribution of FAB-F
u
toPpm to the plasma membrane. In contrast, activation of PPARc
failed to change the subcellular distribution of FAT/CD36 and FAB-
Ppm. These PPARa-, and PPARb/d-induced changes in the plasma-
lemmal content of the fatty acid transporters were also associated
with the concurrent upregulation of fatty acid oxidation. Impor-
tantly, the increase in fatty acid oxidation was greater when both
plasmalemmal FAT/CD36 and FABPpm were increased (PPARb/d
activation). These effects were independent of the activation of
either AMPK or ERK1/2 and were not related to the changes in
FFA serum. The administration of either pioglitazone (PPARc) or
GW0742 (PPARb/d) decreased serum free fatty acid concentration,
but stimulation of PPAR a (WY 14 643) had no effect on serum FFA
(Table 1). Previously, rosiglitazone (another PPARc activator) has
been found to reduce serum fatty acid concentration in obese Zuc-
ker rats [40], but not in obese mice [41]. Similarly, the reduction of
FFA serum levels was observed after the treatment with GW0742
[42]. In contrary, treatment with WY 14 643 results in either no
change in circulating fatty acids [43] or reduction in NEFAs (Non-
Esteriﬁcated Fatty Acids) [44,45]. It is well known that, protein-
mediated LCFAs transport depends on plasma concentrations of
fatty acids and appears to be upregulated when the LCFA milieu
is increased by a high fat diet or by fasting [46,47]. Accordingly,
neonatal cardiac myocytes exposed to high concentrations of pal-
mitate revealed FAT/CD36 mRNA upregulation [47]. Importantly,
LCFAs and a variety of related compounds are known ligands for
PPARs and observed effects of in these studies likely were related
to PPARs activation. However, despite the importance of PPARs in
the regulation of cardiac lipid metabolism and energy homeostasis,
very few studies examined the inﬂuence of PPARs activation on FA
transporters expression [44]. Nonetheless, in our study, serum FFA
levels were not related to the changes in FAT/CD36 and FABPpm
(Got2) expressions (protein and mRNA) nor their plasmalemmal
content (Table 1). This leaves the opportunity to speculate whether
in vivo activation of PPARs directly inﬂuences myocardial expres-
sion of fatty acids transporters. It has recently been shown that
transgenic mice with cardiac-speciﬁc over-expression of PPARa
[myosin heavy chain (MHC)-PPAR mice] develop severe cardiomy-
opathy associated with marked myocardial lipid accumulation and
increased myocardial expression of FAT/CD36 mRNA [27,48]. In
our present study we show that in vivo PPARa stimulation in-
creased transcript FAT/CD36 mRNA content, although did not
change the total protein FAT/CD36 expression. Importantly, PPARa
activation induced also FAT/CD36 translocation to the cardiac
myocyte plasmalemma, with concomitant upregulation in palmi-
tate uptake. In contrast to PPARa stimulation, PPARb/d activation
Fig. 6. Effects of PPAR‘s stimulation on the AMPK, ERK1/2 cytosolic expression.
Table 1
Summary of the results.
Treatment mRNA Total expression PM expression Uptake Oxydation PL TG DG Serum FFA
PPARa/WY 14 643 CD36 – " FABPpm – NS CD36 – NS FABPpm – NS CD36 – " FABPpm – NS " " NS NS " NS
PPARb/d/GW0742 CD36 – " FABPpm – NS CD36 – " FABPpm – NS CD36 – " FABPpm – " " " " " NS " NS ;
PPARc/Pioglitazone CD36 – NS FABPpm – NS CD36 – NS FABPpm – NS CD36 – NS FABPpm – NS ; ; NS NS NS ;
NS – not signiﬁcant.
" – treatment vs. control.
; – treatment vs. control.
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mRNA) and plasmalemmal FAT/CD36 expression. Moreover, we
observed also FABPpm translocation following PPARb/d stimula-
tion. Redistribution of both fatty acid transporters (FAT/CD36 and
FABPpm) to the plasma membrane was accompanied by marked
increase in palmitate uptake, which was distinctly greater than
with PPARa stimulation. These provide strong evidence for PPARa
and PPARb/d contribution to the protein-mediated fatty acids
transport in the heart. Previous studies have shown that mice with
cardiomyocyte-restricted PPARb/d deletion exhibit impaired lipid
metabolism, progressive myocardial lipid accumulation, cardiac
hypertrophy and in consequence heart failure [49]. Conversely,
chronic treatment with a highly selective PPARb/d agonist
(GW610742) in a rat model of congestive heart failure, improved
fat oxidation rate, minimizing adverse manifestations of the dis-
ease [29]. The absence of any effect of PPARc on fatty acid trans-
porters and metabolism are in accordance with previous studies
in which PPARc activation failed to alter cardiac expression of
FAT/CD36 mRNA and the mRNAs of other metabolic genes
[22,47]. Thus, our study and others [22,47] argue against PPARc
major contribution to the regulation of cardiac lipid metabolism.
It is likely that the negligible effects of PPARc activation on fattyacids transport and oxidation are related to its low abundance in
the heart [22].
Recent evidence has revealed that protein-mediated cardiac
fatty acid transport across plasma membranes is regulated by
activation of different intracellular signaling pathways such as
PI3K/Akt (insulin) [14,37,39] or AMPK, MAPK (AICAR, contrac-
tions) or PKC [15,50,51]. Acute effects of various stimuli induced
the translocation of only FAT/CD36 (insulin) and at times FABPpm
(AMPK activation), from intracellular depots to the plasma mem-
brane and in consequence increased the rate of fatty acid uptake
into cardiomyocytes [14,15,37,39]. Present study shows that pos-
sible involvement of either AMPK or ERK1/2 in the redistribution
of both FAT/CD36 and FABPpm from intracellular pool to the plas-
ma membrane plays rather a minor or permissive role in chronic,
in vivo PPARa and PPARb/d activation. It is hard to address in vivo
PPAR activation with relation to the intracellular signaling path-
ways as too many factors (hormone and/or substrate milieu)
may account for the observed effects. Furthermore, it seems likely
that this PPARs effect occurs independently of the activation of
either AMPK or ERK1/2 as others observed also lack of signiﬁcant
changes in the expression and activity of AMPK in PPARa deﬁ-
cient mice [52].
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ing that changes in palmitate uptake are distinctly correlated with
the plasmalemmal content of FAT/CD36. In consideration of ours
and other researcher’s ﬁndings, FAT/CD36 appears as a major
player among fatty acid transporters in the heart [13–15]. How-
ever, it is still possible, that FAT/CD36 and FABPpm may collabo-
rate in facilitating FA transport across the plasma membrane
[5,11,53]. This might be further suggested by PPARb/d activation
which resulted in far more abundant fatty acid uptake when the
plasmalemmal content of both FAT/CD36 and FABPpm was in-
creased (Table 1).
The metabolic consequence of PPARa and PPARb/d activation in
the present study was a signiﬁcant increase in palmitate oxidation
in intact, perfused hearts. In contrast, we observed a reduction in
palmitate oxidation after PPARc treatment. Our ﬁndings are in
accordance with several previous studies indicating the pivotal
role of PPARa and PPARb/d in fatty acid utilization in cardiac myo-
cytes, suggesting that both PPARs share a similar role in cardiac
cells regarding lipid metabolism [20,22]. Interestingly, we ob-
served a decrease in myocardial FA oxidation followed by PPARc,
but we can speculate that PPARc-mediated decrease in FA oxida-
tion is rather based on decreased fatty acids plasma concentration.
Apart from stimulating fatty acid oxidation, we also observed a sig-
niﬁcant increase in palmitate incorporation into diacylglycerols
and triacylglycerols after PPARa and PPARb/d activation, respec-
tively. In our opinion, the intensiﬁcation of fatty acids incorpora-
tion into different lipid pools may be simply the result of FA
uptake upregulation, as these lipid fractions may serve as tempo-
rary fatty acids storage in cardiac myocytes.
5. Conclusions
Our results indicate that PPARa and PPARb/d activation, but not
PPARc, can upregulate fatty acid uptake and oxidation in the heart
by inducing the translocation of FAT/CD36 (PPARa and PPARb/d)
and at times FABPpm (PPARb/d) to the plasma membranes. Impor-
tantly, observed effects of chronic PPARs activation were not re-
lated to either AMPK or ERK1/2 activation or serum FFA levels.Acknowledgements
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